Trump Delays Tariff Increases on Furniture and Cabinets for One More Year 
Wall Street Ends Mixed as Tech and Financial Stocks Weigh on Markets Amid Thin Holiday Trading 
Oil Prices Slip Slightly as Markets Weigh Geopolitical Risks and Supply Glut Concerns 
USDA $12 Billion Farm Aid Program Draws Mixed Reactions from Row Crop Farmers 
Forex Markets Hold Steady as Traders Await Fed Minutes Amid Thin Year-End Volumes 
U.S. Dollar Steadies Ahead of Fed Minutes as Markets Eye Policy Divisions 
Asian Stock Markets Start New Year Higher as Tech and AI Shares Drive Gains 
U.S. Dollar Starts 2026 Weak as Yen, Euro and Sterling Hold Firm Amid Rate Cut Expectations 
Federal Reserve Begins Treasury Bill Purchases to Stabilize Reserves and Money Markets 
China Manufacturing PMI Rebounds in December, Offering Boost to Economic Growth Outlook 
South Korea Exports Hit Record High as Global Trade Momentum Builds 
Asia Manufacturing PMI Rebounds as Exports and Tech Demand Drive Growth into 2026 
Citi Forecasts a Volatile but Ongoing Bull Market for S&P 500 in 2026 
U.S. Stock Futures Slip as Year-End Trading Turns Cautious 
U.S. Stock Index Futures Steady as Markets Await Fed Policy Clues in Holiday-Thinned Trade 
South Korea Inflation Rises to 2.3% in December, Matching Market Expectations 
Swiss pharmaceutical leader Roche confirmed it has no plans for layoffs, emphasizing a healthy business outlook. CEO Thomas Schinecker highlighted steady research funding and workforce stability despite global economic challenges in Europe and China, as well as setbacks in cancer drug development.
Roche Maintains Workforce Stability Amid Market Challenges
Roche, a Swiss pharmaceutical corporation, does not intend to reduce its workforce, and the company's business is doing well. According to a statement made by CEO Thomas Schinecker, which was published in a Swiss publication on Sunday, Investing.com shares.
The stock price of Roche has dropped significantly below the highs it reached in April 2022, and the CEO was questioned about the company's plans for personnel in light of recent setbacks in the company's efforts to produce pharmaceuticals to cure a variety of illnesses, including cancer.
Schinecker responded to a question about whether or not the company was preparing to lay off employees by saying, "The number of workers is constant to slightly increasing," during an interview with the NZZ am Sonntag.
Research and Development Budgets Remain Steady
"I can say with certainty that we have a very healthy business. And we don't have a growth problem either," he remarked, pointing out that Roche's funding for research and development was consistent and not expanding. He also included this information in his statement.
When Schinecker was asked when Roche's intended anti-obesity medicine would be available for purchase, he responded that it may be as early as 2029 or perhaps earlier.
European Economic Struggles Create Headwinds for Recovery
While discussing the forecast for the coming year in a broader sense, particularly in light of the recent difficulties that the German economy has been experiencing, the CEO of Roche stated that Europe still faced problems.
"There's some economic growth in the United States, but things are more difficult in China at the moment," he explained to reporters. "And in Europe it will take some time before we get out of this."
